The Deleterious Effect of Insulin Therapy: A Possible Correlation With Increased Neoplasm Mortalities in the T2DM Population
Abstract
Background: Diabetes mellitus (T2DM) is a significant health problem in the United States and throughout the world. Current treatment protocol advises weight reduction, healthy diet, and anti-diabetic medication as first-line therapy; however, many T2DM patients rapidly transition to an insulin regimen. Insulin is the most effective treatment in reducing blood glucose levels; however, it is associated with mitogenic effects. These effects, in addition to T2DM and its co-morbidities, may be responsible for a higher prevalence of mortality in those who develop malignancies.
Methods: An exhaustive literature search utilizing Google Scholar, MEDLINE-Ovid, Web of Science, and CINAHL was conducted. The following search terms were used independently and in combination: neoplasm, mortality, cancer, insulin, and T2DM. Reviewed studies were assessed for quality using GRADE.
Results: Thirty-four articles were reviewed for relevancy. Three were included in this systematic review, designed as cohort studies, and demonstrated an increased rate in neoplasm mortality among insulin-treated type II diabetics. Of note, the Gu et al study found that the insulin therapy group experienced a significantly higher cancer mortality rate (fully adjusted RR=2.16, 95% CI 1.39–3.35, P=0.001) compared with non-insulin users. The third study also demonstrated a risk in that the insulin-treated cohort experienced greater cancer-related deaths than persons using metformin (1.9 (95% CI 1.5–2.4; P < 0.0001).
Conclusion: Insulin treatment in T2DM may be associated with increased neoplasm mortalities. In the three observational cohort studies, insulin use has been associated with a higher prevalence of cancer death. Despite the evidence presented in this systemic review, further studies are recommended to confirm the data.
Keywords: Neoplasm, mortality, cancer, insulin, type II diabetes mellitus
(Click on image to enlarge.)
REVIEWED STUDIES:
Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care. 2006;29(2):254-258.
Forssas E, Sund R, Manderbacka K, Arffman M, Ilanne-Parikka P, Keskimaki I. Increased cancer mortality in diabetic people treated with insulin: a register-based follow-up study. BMC Health Services Research. 2013;13:267.
Gu Y, Wang C, Zheng Y, Hou X, Mo Y, et al. Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai. PLoS ONE. 2013;8(1): e53411. doi:10.1371/journal.pone.0053411
AUTHOR: Edmund Concepcion is currently completing his second year in the School of PA Studies at Pacific University, Oregon. He will graduate with an MS degree in August 2017.
No Comments Yet